{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-007076","form_type":"8-K","ticker":"UG","cik":"0000101295","company_name":"UNITED GUARDIAN INC","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.524533+00:00","generated_at":"2026-05-16T23:18:46.631324+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"United-Guardian Q3 revenue down 26% YoY; net income falls 69% to $0.06 EPS","bullets":["Q3 2025 revenue $2.26M vs $3.06M in Q3 2024; net income $268K vs $865K.","Nine-month revenue $7.58M (-22%); net income $1.46M (-47%); EPS $0.32 vs $0.60.","Decline driven by reduced orders from ASI for cosmetic ingredients due to tariff/geopolitical issues.","Pharmaceutical and medical sales rose 10% and 6% respectively in first nine months.","Company advancing Renacidin formulary inclusion project to boost pharmaceutical revenue."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-007076","json":"https://secwatch.observer/filing/0001171843-25-007076.json","markdown":"https://secwatch.observer/filing/0001171843-25-007076.md","text":"https://secwatch.observer/filing/0001171843-25-007076.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/101295/000117184325007076/0001171843-25-007076-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/101295/000117184325007076/f8k_110425.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:18:46.631324+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}